These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 35274403)
21. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752 [TBL] [Abstract][Full Text] [Related]
22. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585 [TBL] [Abstract][Full Text] [Related]
23. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881 [TBL] [Abstract][Full Text] [Related]
24. Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study. Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J; Int J Drug Policy; 2024 May; 127():104394. PubMed ID: 38608357 [TBL] [Abstract][Full Text] [Related]
25. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194 [TBL] [Abstract][Full Text] [Related]
26. Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. Midgard H; Bjørnestad R; Egeland M; Dahl E; Finbråten AK; Kielland KB; Blindheim M; Dalgard O Liver Int; 2022 Jun; 42(6):1268-1277. PubMed ID: 35362660 [TBL] [Abstract][Full Text] [Related]
27. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden. Kågström E; Lannergård A; El Khosht J; Lörelius P; Månflod J; Strömdahl S Harm Reduct J; 2023 Jun; 20(1):77. PubMed ID: 37328868 [TBL] [Abstract][Full Text] [Related]
28. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar. Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155 [TBL] [Abstract][Full Text] [Related]
29. Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs. Latham NH; Pedrana A; Doyle JS; Howell J; Williams B; Higgs P; Thompson AJ; Hellard ME J Viral Hepat; 2019 Jul; 26(7):919-922. PubMed ID: 30801881 [TBL] [Abstract][Full Text] [Related]
30. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. Byrne CJ; Radley A; Inglis SK; Beer L; Palmer N; Duc Pham M; Allardice K; Wang H; Robinson E; Hermansson M; Semizarov D; Healy B; Doyle JS; Dillon JF Aliment Pharmacol Ther; 2022 Jun; 55(12):1512-1523. PubMed ID: 35538396 [TBL] [Abstract][Full Text] [Related]
31. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863 [TBL] [Abstract][Full Text] [Related]
32. Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. Forns X; Colom J; García-Retortillo M; Quer JC; Lens S; Martró E; Domínguez-Hernández R; Casado MÁ; Buti M J Viral Hepat; 2022 Mar; 29(3):227-230. PubMed ID: 34806812 [TBL] [Abstract][Full Text] [Related]
33. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB; J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684 [TBL] [Abstract][Full Text] [Related]
34. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark. Demant J; Krohn-Dehli L; Van der Veen J; Øvrehus A; Lazarus JV; Weis N Int J Drug Policy; 2023 Nov; 121():104185. PubMed ID: 37774576 [TBL] [Abstract][Full Text] [Related]
35. Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers. Fontaine G; Presseau J; Bruneau J; Etherington C; Thomas IM; Hung JC; van Allen Z; Patey AM; Kareem A; Mortazhejri S; Høj SB; Boyer-Legault G; Grimshaw JM Int J Equity Health; 2024 Jun; 23(1):124. PubMed ID: 38886803 [TBL] [Abstract][Full Text] [Related]
36. Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia. Uusküla A; Talu A; Rannap J; Barnes DM; Jarlais DD Harm Reduct J; 2021 Apr; 18(1):39. PubMed ID: 33794927 [TBL] [Abstract][Full Text] [Related]
37. Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness. Rajkumar N; Khumukcham LS; Thangjam D; Singh S; Khwairakpam G; Shilton S; Goel A Harm Reduct J; 2024 May; 21(1):98. PubMed ID: 38769517 [TBL] [Abstract][Full Text] [Related]
38. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]